banner-img-2 mobile-banner-img

I am interested in booking my lumella

Introducing the rapid point-of-care
test in early detection of preeclampsia

 

Early & Effective Screening can help save lives

Testing period: Gestational age 13-37 weeks

 

The Lumella test estimates the concentration of Glycosylated Fibronectin, a new pregnancy specific biomarker to accurately assess the risk of preeclampsia

card-img1
icon1-Jun-30-2021-10-27-47-13-AM
Measures glycosylated fibronectin (GlyFN)
card-img2
icon2-Jun-30-2021-10-27-47-15-AM
Uses 5 μL finger prick blood sample
card-img3
icon3-Jun-30-2021-10-27-47-21-AM
Results in 10 minutes

Early Symptoms of Preeclampsia are often too Ambiguous for Accurate Clinical Stratification

Clinical presentations often involve uncertain indications of hypertension and proteinuria
Less than 40% of women exhibit both hypertension and proteinuria before the development of overt preeclampsia
Preeclampsia progression is unpredictable and often complicated by adverse outcomes
 

The Lumella® GlyFN Test is intended as an aid in the diagnosis of women with suspected Preeclampsia.

-Rasanen-et-al
Normal GlyFN 50-250μg/mL Correlated with normal pregnancy with high sensitivity of 98.2% and high Negative Predictive Value of 99.4%
Positive GlyFN 351-600 μg/mL Correlated with biochemical diagnosis of preeclampsia with 98% Positive Predictive Value
High Positive GlyFN >600 μg/mL Correlated with risk of severe preclampsia with 99% Positive Predictive Value